Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Viridian Therapeutics reports strong progress in 2022 with promising trials

Viridian Therapeutics made significant strides in 2022 with positive data on VRDN-001 and plans for Phase 3 trials.
Financially, the company remains strong with $424.6 million in cash, despite increased R&D expenses.
The company's expansion into rare diseases, leadership transition, and strategic clinical site targeting showcase growth potential.
Challenges include dosing frequency impact on efficacy and operational hurdles in patient enrollment and market competition.

Viridian Therapeutics reports strong Q1 performance and strategic advancements

Viridian Therapeutics demonstrated strong performance in clinical trials and financial stability, supported by key hires and strategic partnerships, while facing challenges in investor communication and market access strategies.
The company's focus on innovation in drug delivery methods and pipeline expansion presents opportunities for growth and competitive differentiation in the biopharmaceutical industry.
Overall, Viridian's proactive approach to advancing therapeutic programs and addressing investor concerns positions the company well for future success and potential market impact.

Viridian Therapeutics excels in pipeline progress and financial stability

Viridian Therapeutics showcased strong pipeline progress and financial stability in Q1 2024, with confidence in their transformative therapies.
While facing challenges in regulatory processes and market competition, the company is poised for growth through upcoming program milestones.
Opportunities lie in expanding their therapeutic portfolio, demonstrating product efficacy, and navigating regulatory pathways effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 173,000 shares of the company's common stock to.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.27 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ending June 30, 2024. “Our team continues to execute across the board as shown by the progress we have made this quarter, and we are proud to report solid progress in our TED portfolio, with both VRDN-001 pha.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Catalyst Pharmaceuticals

Verona Pharma

As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks You May Want To Dump This Quarter

Candel Therapeutics

Rocket Pharma

The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.

3 Biotech Names With Potential Catalysts By Year End

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in THRIVE-2, its phase 3 clinical trial for VRDN-001 in patients with chronic TED. THRIVE-2 enrolled 188 patients globally and exceeded the enrollment target of 159 patients due to patient demand. Approximately 40% of the enrolled patients were from U.

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics (VRDN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?

ChargePoint Holdings

ExScientia Ltd

Small-cap stocks, typically valued between $300 million and $2 billion, often promise notable growth potential and superior long-term returns. Now, with interest rate cuts on the horizon, investors are speculating which high-growth small-cap stocks may thrive.

3 Small-Cap Stocks With Explosive 2X Growth Potential

Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients are the most important catalysts for the company this year. Matching Tepezza's efficacy and safety would be considered a win, but there is potential for better efficacy and safety.

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Viridian Therapeutics VRDN has announced detailed plans for a late-stage program on VRDN-003, its investigational subcutaneously (SC)-administered antibody, in patients with moderate-to-severe thyroid eye disease (TED).

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED. “We are very pleased to have completed a positive Type C meeting with the FDA and to take this next step towards rapidly bringing a hi.

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference (New York, NY): Presentation on Wednesday, June 5, 2024, at 5:00 p.m. ET. Goldman Sachs 45th Annual Global Healthcare Conference (Miami, FL).

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare Conference (New York, NY): Presentation on Tuesday, May 14, 2024, at 8:30 a.m. ET. BofA Securities 2024 Health Care Conference (Las Vegas, NV): Present.

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Louisa Stone – Manager of Investor Relations Steve Mahoney – President and CEO Tom Ciulla – Chief Medical Officer Conference Call Participants Laura Chico – Wedbush Alex Thompson – Stifel Michael Yee – Jefferies Gavin Clark-Gartner – Evercore Rami Katkhuda – LifeSci Capital Gregory Renza – RBC Julian Harrison – BTIG Trevor Allred – Oppenheimer Operator Welcome to the Viridian Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.

Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.61 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ending March 31, 2024. “It has been a remarkable first quarter of execution as we made progress across our TED and neonatal Fc receptor (FcRn) inhibitor programs,” said Steve Mahoney, Viridian President and Ch.

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

PALO ALTO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Multifamily owner-operator and investment manager Pacific Urban Investors (“Pacific”) has acquired Viridian, a 420-unit apartment community in Greenwood Village, CO. Viridian (the “Property”) is located in the Denver Tech Center, adjacent to thousands of high paying technology, financial services, telecommunications, and aerospace jobs. The acquisition marks Pacific's fourth investment in the Denver market with the firm's regional portfolio now totaling 884 units.

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights. The webcast can be accessed under “Events and Presentations” on the Investors section of the Viridian website at vir.

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

PHILADELPHIA , March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's shareholders. The investigation seeks to determine whether Viridian and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's shareholders in connection with recent corporate actions.

VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm

Genius Sports

SkyWater Technology

Inflation has been the scourge of American households since the Covid-19 disruption. But investors can attempt to beat rising prices with stocks under $20.

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Investors section of the Viridian w.

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to a 97.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023. “Throughout 2023, we delivered important clinical results across our TED portfolio, marking significant progress for the company,” said Steve Mahoney, Viridian President.

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer. “I am very pleased to welcome Jennifer to Viridian to lead our legal team and join Viridian's executive team ahead of an exciting set of milestones this year across our t.

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 30,000 shares of the company's common stock.

News for Viridian Therapeutics Stock (VRDN)